Alimera Sciences, Inc. acquired YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.
May 17, 2023
Share
Alimera Sciences, Inc. acquired YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million on May 17, 2023. Under the terms of the agreement, EyePoint received a $75 million up front cash payment at closing and will receive an additional earn out payment of $7.5 million in equal quarterly installments in 2024. Alimera funded the upfront payment and obtained additional working capital with $69 million private placement (Tranche 2 ) of Series B preferred stock and common stock to a syndicate of investors led by Velan Capital and Caligan Partners. The proceeds from the Tranche 2 Closing were used to fund a portion of the upfront cash payment due upon our acquisition of the exclusive U.S. commercialization rights for YUTIQ. Tranche 2 consist of being issued and sold an aggregate of 66,617 shares of Series B Preferred at a per-share purchase price equal to the Stated Value and 1,401,901 shares of common stock at a per-share purchase price equal to $1.70 for aggregate gross proceeds of $69.0 million. Borrowing of an additional $20 million through an amendment to its existing term loan agreement with SLR Capital Partners, LLC. Under the terms of the agreement, Alimera will receive global rights to YUTIQ outside of China, Hong Kong, Taiwan, Macau and Southeast Asia. YUTIQ was approved by the U.S. Food and Drug Administration for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ has sixty percent revenue growth in first quarter of 2023. Sidley Austin LLP acted as legal advisor to EyePoint Pharmaceuticals, Inc. Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP acted as legal advisor to Alimera Sciences, Inc. YUTIQ reported revenues of $28.329 million for the year ended December 31, 2022.
Alimera Sciences, Inc. completed the acquisition of YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million on May 17, 2023.
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Companyâs other products include YUTIQ, and DEXYCU.